Tyme Technologies

TYME Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s immune system.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership team will present at the BioNJ 10th Annual BioPartnering Conference on Tuesday, October 6, 2020.

Tyme Technologies to Present at BioNJ’s 10th Annual BioPartnering Conference on October 6, 2020

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020.

Tyme Technologies to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will participate at the H.C.

Tyme Technologies to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

TYME’s Oncology Research Reveals Potential New Oral Therapy TYME-19 in the Fight Against COVID-19

Tyme Technologies to Present at the 2020 CHINABIO® Partnering Forum

TYME Announces Outcome of Interim Futility Review for HopES Sarcoma Phase II Study

Tyme Technologies (NASDAQ: TYME) shares are trading higher on Monday after the company announced an orphan drug designation for its SM-88 as a potential treatment for patients with pancreatic cancer.

Why Tyme Technologies's Stock Is Trading Higher Today

TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will participate at the Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020.

Tyme Technologies to Present at Canaccord 40th Annual Growth Conference on August 13, 2020

Tyme Technologies Inc (NASDAQ:TYME) was trading 1.7% lower from the previous closing price.

Insider Sells Tyme Technologies' Stock

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced preliminary financial and operating results for its first fiscal quarter ended June 30, 2020. During first quarter fiscal 2021, the Company presented a growing body of preclinical and clinical data at major international medical meetings; continued enrolling patients in multiple studies including, second and third-line pancreatic c

TYME Provides Business Update and Announces Preliminary First Quarter Fiscal 2021 Financial and Operating Results

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that TYME will hold its 2020 Annual Meeting of Stockholders in a virtual-only format, as a result of public health concerns relating to the coronavirus (COVID-19) and to protect the health and well-being of its shareholders, directors, employees and the public, on Thursday, August 20, 2020, at 11:00 AM Eastern Time. Stockholders wi

 Tyme Technologies Announces Virtual 2020 Annual Meeting of Stockholders

Tyme Technologies Inc (NASDAQ:TYME) was trading 0.2% lower from the previous closing price.

Insider Sells Tyme Technologies Shares

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced new preclinical findings that describe the unique anti-cancer effects of its cancer metabolism-based pipeline candidate, TYME-18, that are being presented at the American Association for Cancer Research 2020 Virtual Meeting from June 22 to June 24, 2020. TYME’s CMBTs are proprietary investigational compounds that leverage cancer’s

TYME-18 Demonstrates Anti-Cancer Effect in New Preclinical Data Presented at AACR 2020

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced new preclinical findings that describe the unique mechanism of action of its lead cancer metabolism-based candidate, SM-88 (racemetyrosine), that are being presented at the American Association for Cancer Research 2020 Virtual Meeting from June 22 to June 24, 2020. TYME’s CMBTs are proprietary investigational compounds that leverag

TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020

Tyme Technologies, Inc. (TYME) CEO Steve Hoffman on Q4 2020 Results - Earnings Call Transcript

Tyme Technologies: Market Volatility Provides Opportunity To Accumulate Ahead Of Catalysts

Circling Back On Tyme Technologies

NEW YORK, Jan.  16, 2020  (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the first sarcoma cancer patient has been dosed at the Sarcoma Oncology Center in the HopES Phase II trial designed to evaluate SM-88 (racemetyrosine) for the treatment of high-risk sarcomas, which are ultra-rare cancers with high unmet medical need. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death.

TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas

Tyme Technologies: Why Investors Should Be Bullish On The Eagle Partnership

Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.

Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study

Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.

Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up

Shares of Tyme Technologies were up 23% in premarket trading on Tuesday after the biotechnology company said it had formed a collaboration with Eagle Pharmaceuticals Inc.

Tyme stock rises on Eage collaboration for cancer drug

MOGU Inc - ADR

Falling knives are companies whose share prices have declined more than 59% over the last 52 weeks.

Wall Street Suggests These Falling Knives

NEW YORK, Nov.  07, 2019  (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Jefferies 2019 London Healthcare Conference on Wednesday and Thursday, November 20 and 21, 2019. In one-on-one sessions, the Company will present its corporate overview for 2019 with a special focus on growth opportunities driven by advances in its science of cancer metabolism and clinical and regulatory developments for its lead candidate SM-88 (racemetyrosine) in metastatic cancers.

News for Tyme Technologies Stock (TYME)